Advancements in Diabetic Kidney Disease Management: Integrating Innovative Therapies and Targeted Drug Development.

INV-202 - Novo Nordisk

lixudebart (ALE.F02) - Alentis Therap

CSL346 - CSL Behring

tozorakimab (MEDI3506) - AstraZeneca

bardoxolone methyl (RTA 402) - Kyowa Kirin, Biogen

http://www.ncbi.nlm.nih.gov/pubmed/38630049

Matthew Satariano; Raghav Shah; Rupesh Raina; Saichidroopi Korada; Shaarav Ghose; Thomas Cahill

Apr 17, 2024